SCHEMBL14176030

SCHEMBL14176030

CS(=O)(=O)CCCOc1cccc2c(-c3ccnc(N[C@H]4CC[C@H](C(=O)N5CCC(O)CC5)CC4)n3)noc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 19/20 0.68
MAPK9 P45984 18/20 0.68
MAPK10 P53779 14/20 0.66
CIT O14578 1/20 0.66
DAPK3 O43293 1/20 0.66
STK16 O75716 1/20 0.66
PDGFRB P09619 1/20 0.66
EIF2AK2 P19525 1/20 0.66
CDK11B P21127 1/20 0.66
MAPK3 P27361 1/20 0.66
MAPK1 P28482 1/20 0.66
MAPK4 P31152 1/20 0.66
TTK P33981 1/20 0.66
MAP2K4 P45985 1/20 0.66
GSK3A P49840 1/20 0.66
GSK3B P49841 1/20 0.66
CDK7 P50613 1/20 0.66
MAP2K6 P52564 1/20 0.66
DAPK1 P53355 1/20 0.66
LIMK1 P53667 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14768297 1.00 MAPK8 (0.68) MAPK8MAPK9MAPK10CITDAPK3
SCHEMBL14768131 0.96 MAPK8 (0.67) MAPK8MAPK9MAPK10CITDAPK3
SCHEMBL14176034 0.96 MAPK8 (0.67) MAPK8MAPK9MAPK10CITDAPK3
SCHEMBL14176032 0.87 MAPK8 (0.67) MAPK8MAPK9MAPK10CITDAPK3
SCHEMBL5093909 0.87 MAPK8 (0.67) MAPK8MAPK9MAPK10CITDAPK3
SCHEMBL14768126 0.84 MAPK9 (0.49) MAPK8MAPK9MAPK10CITDAPK3
SCHEMBL14176027 0.84 MAPK9 (0.49) MAPK8MAPK9MAPK10CITDAPK3
SCHEMBL14176035 0.82 MAPK8 (0.47) MAPK8MAPK9MAPK10CITDAPK3
SCHEMBL14768371 0.82 MAPK8 (0.47) MAPK8MAPK9MAPK10CITDAPK3
SCHEMBL7888888 0.81 MAPK9 (1.00) MAPK8MAPK9MAPK10CITDAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399462-B2 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain ROCHE PALO ALTO LLC (US) 2013-03-19 US disclosed
US-8399462-B2 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain ROCHE PALO ALTO LLC (US) 2013-03-19 US disclosed
US-20080146565-A1 JNK modulators ROCHE PALO ALTO LLC 2008-06-19 US disclosed
US-20080146565-A1 JNK modulators ROCHE PALO ALTO LLC 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146565-A1 JNK modulators MAPKAPK2, MAPKAPK3, MAP3K10 MAPK8 40/4885MAPK9 43/4885MAPK10 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.